Controversies in stable coronary artery disease (Q28194400)

Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization

Europe PubMed Central

title

Controversies in stable coronary artery disease (English)

0 references

main subject

coronary artery disease

1 reference

1

Lionel H Opie

0 references

Bernard J Gersh

series ordinal

3

object named as

Bernard J Gersh

0 references

Patrick J Commerford

series ordinal

2

object named as

Patrick J Commerford

0 references

language of work or name

English

0 references

publication date

7 January 2006

0 references

published in

The Lancet

0 references

volume

367

0 references

issue

9504

0 references

page(s)

69-78

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Cardiovascular disease risk profiles.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina—Summary Article

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Relative importance of borderline and elevated levels of coronary heart disease risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Increased cardiovascular morbidity and mortality in type 2 diabetes is associated with the glutathione S transferase theta-null genotype: a Go-DARTS study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

The metabolic syndrome--a new worldwide definition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Normal fasting plasma glucose levels and type 2 diabetes in young men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Influence of percutaneous coronary intervention on coronary microvascular resistance index

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Clinical significance, pathogenesis, and management of postprandial hyperglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

C-reactive protein elevation and disease activity in patients with coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

C-reactive protein levels and outcomes after statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

A walnut diet improves endothelial function in hypercholesterolemic subjects: a randomized crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Changes in plasma antioxidant capacity and oxidized low-density lipoprotein levels in men after short-term cranberry juice consumption

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Drinking frequency, mediating biomarkers, and risk of myocardial infarction in women and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Adherence to a Mediterranean diet and survival in a Greek population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Blood levels of long-chain n-3 fatty acids and the risk of sudden death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

On the reanalysis of the GISSI-Prevenzione

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Summary of a scientific conference on preventive nutrition: pediatrics to geriatrics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

1 reference

7 January 2021

Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Exercise prescription and proscription for patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Cardiovascular effects of secondhand smoke: nearly as large as smoking

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Tobacco smoke exposure is associated with the metabolic syndrome in adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Diabetes and atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Statin-associated peripheral neuropathy: review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Clinical practice. Low HDL cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

ACE inhibition in stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

1 reference

7 January 2021

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Meta-analysis of Trials Comparing β-Blockers, Calcium Antagonists, and Nitrates for Stable Angina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Surgery, angioplasty, or medical therapy for symptomatic multivessel coronary artery disease: is there an indisputable "winning strategy" from evidence-based clinical trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Keeping the patient in view: defining the appropriateness of percutaneous coronary interventions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Predictors of quality-of-life benefit after percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angiop

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Inflammatory biomarkers for prediction of outcomes after unprotected left main coronary intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Long-term outcomes of optimized medical management of outpatients with stable coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Long-term outcomes of coronary-artery bypass grafting versus stent implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Methods of coronary revascularization--things may not be as they seem.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Neuropsychological outcome after percutaneous coronary intervention or coronary artery bypass grafting: results from the Stent or Surgery (SoS) Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Impact of embolization during coronary artery bypass grafting on outcome and length of stay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Fixing the heart: must the brain pay the price?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Off-pump coronary artery surgery for reducing mortality and morbidity: meta-analysis of randomized and observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Neurocognitive complications after coronary artery bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Is there cognitive decline 1 year after CABG? Comparison with surgical and nonsurgical controls

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021

Angiographic patterns of restenosis after paclitaxel-eluting stent implantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2967927-0

7 January 2021